Mixed Phase III data for etrolizumab in moderately to severely active ulcerative colitis

In the HIBISCUS I induction study, in people without prior anti-TNF treatment, etrolizumab met the primary endpoint of inducing remission versus placebo, however, in the HIBISCUS II induction study and the LAUREL maintenance study, the primary endpoints were not met.

Source:

PharmaTimes